SCHEMBL18615912

SCHEMBL18615912

N#CC1(NC(=O)C2(NC(=O)c3cc4ccc(-c5ccc6c(c5)OCCS(=O)(=O)C6)cc4o3)CCC(F)(F)CC2)CC1

nearest known ligand 0.35

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ CTSL P07711 1/20 0.35
▸ CTSK P43235 2/20 0.30
▸ CTSS P25774 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20335462 0.93 CTSL (0.35) CTSLCTSKCTSS
SCHEMBL18616010 0.87 SMN1; SMN2 (0.40) CTSLCTSKCTSS
SCHEMBL18615926 0.86 CTSL (0.34) CTSL
SCHEMBL23810296 0.85 CTSL (0.33) CTSL
SCHEMBL23810290 0.84 CTSL (0.33) CTSL
SCHEMBL18615944 0.83 HPGD (0.39) CTSLCTSKCTSS
SCHEMBL18616686 0.82 CTSL (0.38) CTSLCTSKCTSS
SCHEMBL18616637 0.82 CTSL (0.38) CTSLCTSKCTSS
SCHEMBL18615920 0.82 CTSS (0.39) CTSLCTSKCTSS
SCHEMBL18616557 0.82 CTSL (0.38) CTSLCTSKCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3342765-B1 CATHEPSIN K INHIBITOR AND APPLICATION THEREOF SUNSHINE LAKE PHARMA CO LTD (CN) 2021-09-15 — — EP disclosed
EP-3342765-B1 CATHEPSIN K INHIBITOR AND APPLICATION THEREOF SUNSHINE LAKE PHARMA CO LTD (CN) 2021-09-15 — — EP disclosed
EP-3342765-A1 CATHEPSIN K INHIBITOR AND APPLICATION THEREOF Sunshine Lake Pharma Co., Ltd. (CN) 2018-07-04 — — EP disclosed
EP-3342765-A1 CATHEPSIN K INHIBITOR AND APPLICATION THEREOF Sunshine Lake Pharma Co., Ltd. (CN) 2018-07-04 — — EP disclosed
WO-2017036357-A1 CATHEPSIN K INHIBITOR AND APPLICATION THEREOF 广东东阳光药业有限公司 2017-03-09 — — WO disclosed
Send feedback